Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huangqi Xiaobai is a Traditional Chinese Medicine (TCM) formula, specifically prepared as granules, currently under clinical investigation for the treatment of IgA Nephropathy (IgAN), particularly in patients with Stage CKD1-2. Its therapeutic approach is described within the TCM framework as a "Dampness Dispelling, Blood Stasis Resolving, and Spleen Invigorating Method." This suggests a multi-faceted action aimed at modulating immune responses, reducing inflammation, and improving overall renal function, consistent with general TCM strategies for IgAN. The formula likely contains Astragalus membranaceus (Huang Qi), a prominent herb known for its immunoregulatory, antioxidant, and anti-inflammatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Huangqi Xiaobai.